Stock MVIR B MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medivir AB

Equities

MVIR B

SE0020181014

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:59:59 08/05/2024 BST 		5-day change 1st Jan Change
3.03 SEK +1.00% Intraday chart for Medivir AB -3.81% +6.32%
05-07 Medivir Aktiebolag Approves Board Appointments CI
04-30 Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 301.2 201.5 624.1 551.7 159.1 339.5 - -
Enterprise Value (EV) 1 210.5 131.5 402.9 434.3 -10.48 174.8 94.49 295.5
P/E ratio -2.44 x -4.74 x -9.33 x -6.23 x -1.93 x -5.51 x -2.4 x -2.08 x
Yield - - - - - - - -
Capitalization / Revenue 41.8 x 5.11 x 17.5 x 89 x 17.7 x 10.5 x 6.52 x 33.3 x
EV / Revenue 29.2 x 3.34 x 11.3 x 70 x -1.16 x 5.41 x 1.82 x 29 x
EV / EBITDA -1.77 x -3.42 x -6.77 x -5.12 x 0.12 x -2.42 x -3.17 x -2.29 x
EV / FCF -1.41 x -2.07 x -8.27 x -4.25 x 0.17 x -3.88 x -0.56 x -1.45 x
FCF Yield -71.1% -48.3% -12.1% -23.5% 572% -25.7% -180% -69%
Price to Book 1.63 x 1.42 x 2.22 x 2.86 x 0.79 x 1.1 x 1.11 x 3.26 x
Nbr of stocks (in thousands) 24,288 24,276 55,724 55,724 55,830 112,042 - -
Reference price 2 12.40 8.300 11.20 9.900 2.850 3.030 3.030 3.030
Announcement Date 13/02/20 26/02/21 15/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.2 39.4 35.7 6.2 9 32.3 52.05 10.2
EBITDA 1 -118.9 -38.5 -59.5 -84.8 -88.7 -72.2 -29.8 -129
EBIT 1 -126 -42.9 -62.1 -87.4 -91.4 -79.37 -92.8 -163.4
Operating Margin -1,750% -108.88% -173.95% -1,409.68% -1,015.56% -245.72% -178.29% -1,601.78%
Earnings before Tax (EBT) 1 -123.3 -42.6 -62.6 -88.8 -89.3 -75.1 -92.23 -163.1
Net income 1 -123.4 -42.6 -63.1 -88.8 -89.3 -75.1 -92.23 -163.1
Net margin -1,713.89% -108.12% -176.75% -1,432.26% -992.22% -232.51% -177.19% -1,598.59%
EPS 2 -5.080 -1.750 -1.200 -1.590 -1.480 -0.5500 -1.263 -1.453
Free Cash Flow 1 -149.7 -63.5 -48.7 -102.2 -60 -45 -170 -204
FCF margin -2,079.04% -161.17% -136.41% -1,648.39% -666.67% -139.32% -326.61% -2,000%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 13/02/20 26/02/21 15/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 11.4 18.8 1.7 15.3 0.9 0.9 1.8 2 2.5 0.8 2.6 3.3 1 4.7 0.6 0.9 1.5 1.1 1.2
EBITDA - - - - - - - - - - - - - - - - - - -
EBIT 1 - - - - - -22.1 - -14.6 -18.7 - - - -24.1 -20.8 -27.4 - - - -
Operating Margin - - - - - -2,455.56% - -730% -748% - - - -2,410% -442.55% -4,566.67% - - - -
Earnings before Tax (EBT) 1 -36.1 -25.4 -12.8 -24.3 -32.7 -23.1 -55.9 -14.8 -18.1 -18.9 -26.6 -45.5 -23.6 -20.3 -26.1 -24.3 -34.4 -24.8 -25.3
Net income 1 -36.1 -25.5 -13.3 -24.3 -32.7 -23.1 -55.9 -14.8 -18.1 -18.9 -26.6 -45.5 -23.6 -20.3 -26.1 -24.3 -34.4 -24.8 -25.3
Net margin -316.67% -135.64% -782.35% -158.82% -3,633.33% -2,566.67% -3,105.56% -740% -724% -2,362.5% -1,023.08% -1,378.79% -2,360% -431.91% -4,350% -2,700% -2,293.33% -2,254.55% -2,108.33%
EPS 2 -1.490 -0.5700 -0.2600 -0.4400 -0.5900 -0.4200 -1.000 -0.2700 -0.3200 -0.3400 -0.4700 -0.8100 -0.4200 -0.2800 -0.2300 -0.2100 -0.3000 -0.2100 -0.2200
Dividend per Share - - - - - - - - - - - - - - - - - - -
Announcement Date 20/08/20 19/08/21 03/11/21 15/02/22 28/04/22 19/08/22 19/08/22 03/11/22 15/02/23 27/04/23 18/08/23 18/08/23 27/10/23 15/02/24 30/04/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 90.6 70 221 117 170 165 245 44
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -150 -63.5 -48.7 -102 -60 -45 -170 -204
ROE (net income / shareholders' equity) -50.2% -26.1% -29.8% - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 7.590 5.840 5.040 3.460 3.610 2.760 2.740 0.9300
Cash Flow per Share - - - - - - - -
Capex 1 1.44 5.4 - 0.4 0.3 - 1 3
Capex / Sales 19.94% 13.71% - 6.45% 3.33% - 1.92% 29.41%
Announcement Date 13/02/20 26/02/21 15/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Medivir AB

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.03 SEK
Average target price
20.62 SEK
Spread / Average Target
+580.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDIVIR AB Stock Medivir AB
+6.32% 31.14M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.97% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 105B
ARGENX SE Stock argenx SE
+1.57% 23.46B
BIONTECH SE Stock BioNTech SE
-12.77% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.50% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.00% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.20% 12.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. Financials Medivir AB